9.33

1.79% -0.17

After Hours: 9.38 0.05 +0.54%

Zevra Therapeutics Inc (ZVRA)

Overview News Price History Option Chain Discussions Forecast Stock Split

Zevra Therapeutics Inc stock is traded at $9.33, with a volume of 227.51K. It is down -1.79% in the last 24 hours and up +12.95% over the past month. Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Previous Close:

$9.50

Open:

$9.49

24h Volume:

227.51K

Relative Volume:

0.27

Market Cap:

$498.00M

Revenue:

$27.46M

Net Income/Loss:

$-46.05M

P/E Ratio:

-9.9255

EPS:

-0.94

Net Cash Flow:

$-33.83M

1W Performance:

-2.66%

1M Performance:

+12.95%

6M Performance:

+103.05%

1Y Performance:

+91.58%

1-Day Range:

$9.31

$9.525

1-Week Range:

$9.31

$9.76

52-Week Range:

$4.20

$9.76

Zevra Therapeutics Inc Stock (ZVRA) Company Profile

Name

Zevra Therapeutics Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

(321) 939-3416

Address

1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

ZVRA's Discussions on Twitter

Compare ZVRA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZVRA Zevra Therapeutics Inc	9.33	498.00M	27.46M	-46.05M	-33.83M	-1.29
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-07-24	Initiated	Guggenheim	Buy
Sep-24-24	Initiated	JMP Securities	Mkt Outperform
Sep-24-24	Reiterated	Maxim Group	Buy
Apr-02-24	Reiterated	Maxim Group	Buy
Mar-12-24	Initiated	William Blair	Outperform
Mar-17-23	Initiated	Maxim Group	Buy

View All

Zevra Therapeutics Inc Stock (ZVRA) Latest News

Nov 29, 2024

Vestal Point Capital LP Purchases New Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat

Nov 29, 2024

Nov 26, 2024

179,874 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Purchased by Propel Bio Management LLC - MarketBeat

Nov 26, 2024

Zevra Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times

Nov 26, 2024

Zevra Therapeutics CEO to Present at Major Healthcare Investment Conferences | ZVRA Stock News - StockTitan

Nov 26, 2024

Nov 25, 2024

Zevra Therapeutics' SWOT analysis: rare disease drug maker's stock poised for growth - Investing.com

Nov 25, 2024

Nov 23, 2024

Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 52-Week HighShould You Buy? - MarketBeat

Nov 23, 2024

Zevra launches first FDA-approved NPC treatment By Investing.com - Investing.com Australia

Nov 22, 2024

Nov 21, 2024

Zevra launches first FDA-approved NPC treatment - Investing.com India

Nov 21, 2024

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C - The Manila Times

Nov 21, 2024

HC Wainwright Has Negative Forecast for ZVRA FY2028 Earnings - MarketBeat

Nov 21, 2024

Nov 20, 2024

Zevra Therapeutics (NASDAQ:ZVRA) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 20, 2024

Guggenheim Initiates Coverage of Zevra Therapeutics (ZVRA) with Buy Recommendation - MSN

Nov 20, 2024

Zevra Therapeutics (STU:1GDA) Enterprise Value : €424.12 Mil (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024

Zevra Therapeutics Q3 2024 Earnings Preview - MSN

Nov 20, 2024

Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 20, 2024

Nov 18, 2024

(ZVRA) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 18, 2024

What is William Blair's Forecast for ZVRA FY2024 Earnings? - MarketBeat

Nov 18, 2024

Cantor Fitzgerald Issues Negative Estimate for ZVRA Earnings - MarketBeat

Nov 18, 2024

Nov 16, 2024

Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report - Yahoo Finance

Nov 16, 2024

Nov 15, 2024

Zevra testing beta blocker celiprolol for vEDS in Phase 3 US study - Ehlers-Danlos News

Nov 15, 2024

Simplify Asset Management Inc. Invests $833,000 in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat

Nov 15, 2024

What is William Blair's Estimate for ZVRA FY2026 Earnings? - MarketBeat

Nov 15, 2024

Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results - Simply Wall St

Nov 15, 2024

Roth Capital Forecasts Lower Earnings for Zevra Therapeutics - MarketBeat

Nov 15, 2024

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Sees Large Decline in Short Interest - MarketBeat

Nov 15, 2024

Nov 14, 2024

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 14, 2024

Earnings call: Zevra Therapeutics reports Q3 financial results - Investing.com

Nov 14, 2024

Canaccord Genuity Group Issues Pessimistic Forecast for Zevra Therapeutics (NASDAQ:ZVRA) Stock Price - MarketBeat

Nov 14, 2024

Q4 Earnings Forecast for ZVRA Issued By Roth Capital - MarketBeat

Nov 14, 2024

Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 14, 2024

Nov 13, 2024

Janney Montgomery Scott LLC Sells 127,755 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat

Nov 13, 2024